Clinically, an increased expression of CysLT1R was noted in specimens from gastric cancer [30], renal cell carcinoma [7,8], transitional cell carcinoma [7,9], prostate cancer [7,10], and testicular cancer [7,11]. Here, CYSLTR1 is linked to testicular cancer.